(1-Cyclopentyl-2,2-dioxo-1,2-dihydro-2l6-thia-1,6,8-triaza-naphthalen-7-yl)-[4-(3,5-dimethyl-piperazin-1-yl)-phenyl]-amine | 572915-58-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: (1-Cyclopentyl-2,2-dioxo-1,2-dihydro-2l6-thia-1,6,8-triaza-naphthalen-7-yl)-[4-(3,5-dimethyl-piperazin-1-yl)-phenyl]-amine
• 英文别名: 1-cyclopentyl-N-[4-(3,5-dimethylpiperazin-1-yl)phenyl]-2,2-dioxopyrimido[4,5-c]thiazin-7-amine
• CAS: 572915-58-3
• 化学式: C₂₃H₃₀N₆O₂S
• 分子量: 454.596
• InChiKey: YHAMSEBCHKRGMZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  98.8
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• 2-Thia-1,6,8-Triaza-Naphthalene-2,2-Dioxides are kinase inhibitors
  申请人：——

  公开号：US20030186973A1

  公开（公告）日：2003-10-02

  The present invention provides 2-thia-1,6,8-triaza-naphthalene-2,2-dioxide inhibitors of cyclin-dependent kinases, uses thereof and pharmaceutical compositions thereof. These compounds are useful for treating cell proliferative disorders, such as cancer, atherosclerosis, and restenosis. These compounds are potent inhibitors of kinases such as cyclin-dependent (cdks) and growth factor-mediated kinases. The present invention also provides a method of treating cell proliferative disorders 1

  本发明提供了2-硫代-1,6,8-三氮杂萘-2,2-二氧化物，它们是细胞周期蛋白依赖性激酶的抑制剂，以及它们的应用和制药组合物。这些化合物可用于治疗细胞增殖性疾病，如癌症、动脉粥样硬化和再狭窄。这些化合物是强效的激酶抑制剂，如细胞周期蛋白依赖性激酶（cdks）和生长因子介导的激酶。本发明还提供了一种治疗细胞增殖性疾病的方法。
• US7026313B2
  申请人：——

  公开号：US7026313B2

  公开（公告）日：2006-04-11
• [EN] 2-THIA-1,6,8-TRIAZA-NAPHTALENE-2,2-DIOXIDES AS CDK INHIBITORS<br/>[FR] 2-THIA-1,6,8-TRIAZA-NAPHTALENE-2,2-DIOXYDES INHIBANT LES CDK
  申请人：WARNER LAMBERT CO

  公开号：WO2003062246A1

  公开（公告）日：2003-07-31

  The present invention provides 2-thia-1 ,6,8-triaza-naphthalene-2,2-dioxide inhibitors of cyclin-dependent kinases, uses thereof and pharmaceutical compositions thereof. These compounds are useful for treating cell proliferative disorders, such as cancer, atherosclerosis, and restenosis. These compounds are potent inhibitors of kinases such as cyclin-dependent (cdks) and growth factor-mediated kinases. The present invention also provides a method of treating cell proliferative disorders formula (1).